Long-term treatment outcome with different formulations of botulinum toxin.
M T
MT
Pérez-Saldaña
E K
EK
Tan
J A
JA
Burguera
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D018726:Anti-Dyskinesia Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004351:Drug Resistance; D020820:Dyskinesias / Q000188:drug therapy*; D006801:Humans; D009469:Neuromuscular Junction / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome
D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; D000109:Acetylcholine